Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Teige Ingrid, Rohrberg Kristoffer S, Carneiro Ana, Yachnin Jeffrey, Gertsson Susanne, Holmkvist Petra, Mårtensson Linda, Eefsen Rikke L, Pápai Zsuzsanna, Láng István, Walter Harriet, Borggren Marie, Vaapil Marica, Nilsson Jan Anders, Svensson Carolin, Kovacek Mathilda, Blidberg Therese, Cleary Kirstie, Oldham Robert J, Ferreira Alexandra Gabriela, Duell Benjamin L, Sundstedt Anette, Yoosuf Niyaz, Semmrich Monika, Lindahl Danijela, Beers Stephen A, Lim Sean H, Wallin Johan, Karlsson Ingrid, Cragg Mark S, Frendéus Björn, McAllister Andres
Аннотация
PURPOSE: To clinically evaluate the safety, pharmacodynamic biomarkers, and efficacy of BI-1808, a first-in-class ligand-blocking, Fcγ receptor-engaging anti-TNFR2 antibody, as a novel immunotherapy approach to enhance antitumor immunity in solid cancer patients.
EXPERIMENTAL DESIGN: Preclinical modeling in syngeneic tumor models was used to assess the relationship between dose, pharmacokinetics, receptor occupancy, and efficacy, as well as pharmacodynamic biomarkers measured in peripheral blood and tumors. These findings informed dosing and analyses in a first-in-human phase 1 dose-escalation trial in patients with solid cancers.
RESULTS: BI-1808 was safe and well-tolerated, showed expected pharmacokinetics, and achieved full receptor occupancy throughout the three-week dosing interval. Tumor regression was observed in two patients, one with non-small cell lung cancer and one with gastrointestinal sarcoma. Stable disease was observed in 6 of 21 evaluable patients. Tumor regression was preceded by increases in circulating CX3CR1+CD8+ T cells and tumor-infiltrating CD8+ T cells, consistent with activation of antitumor immunity. Pharmacodynamic analyses were consistent with the preclinically characterized mechanism of action, including dose-dependent reduction of regulatory T cells, monocyte activation, and serum cytokines indicating myeloid reprogramming, tertiary lymphoid structure formation, and CD8+ T-cell activation.
CONCLUSIONS: These early clinical findings support further development of ligand-blocking, Fcγ receptor-engaging anti-TNFR2 antibodies as a safe and mechanistically distinct cancer immunotherapy strategy. The excellent safety profile of BI-1808 makes it well-suited for combination with other immunotherapies, targeted agents, chemotherapeutics, cell therapies, and ADCs.
EXPERIMENTAL DESIGN: Preclinical modeling in syngeneic tumor models was used to assess the relationship between dose, pharmacokinetics, receptor occupancy, and efficacy, as well as pharmacodynamic biomarkers measured in peripheral blood and tumors. These findings informed dosing and analyses in a first-in-human phase 1 dose-escalation trial in patients with solid cancers.
RESULTS: BI-1808 was safe and well-tolerated, showed expected pharmacokinetics, and achieved full receptor occupancy throughout the three-week dosing interval. Tumor regression was observed in two patients, one with non-small cell lung cancer and one with gastrointestinal sarcoma. Stable disease was observed in 6 of 21 evaluable patients. Tumor regression was preceded by increases in circulating CX3CR1+CD8+ T cells and tumor-infiltrating CD8+ T cells, consistent with activation of antitumor immunity. Pharmacodynamic analyses were consistent with the preclinically characterized mechanism of action, including dose-dependent reduction of regulatory T cells, monocyte activation, and serum cytokines indicating myeloid reprogramming, tertiary lymphoid structure formation, and CD8+ T-cell activation.
CONCLUSIONS: These early clinical findings support further development of ligand-blocking, Fcγ receptor-engaging anti-TNFR2 antibodies as a safe and mechanistically distinct cancer immunotherapy strategy. The excellent safety profile of BI-1808 makes it well-suited for combination with other immunotherapies, targeted agents, chemotherapeutics, cell therapies, and ADCs.